About

The vast majority of testosterone users were not seen by an endocrinologist or urologist either before or after initiation of treatment. During this period, 8.9% of testosterone users were seen by an endocrinologist and 20.6% of testosterone users were seen by a urologist (data not shown). During this period, 7.3% of testosterone users were seen by an endocrinologist and 19.5% were seen by a urologist (data not shown). We examined whether or not a patient had seen an endocrinologist or urologist in the 12 months before or 12 months after treatment by examining the provider category field in the outpatient claims data. We assessed whether or not a patient received a laboratory test to evaluate endogenous-free or total testosterone by checking for the presence of CPT codes (84402 and 84403) in any inpatient or outpatient claim. Testosterone therapy was identified using National Drug Codes for topical gel, transdermal patch, and oral formulations (Figure) and health-care common procedure coding system (HCPCS) codes for injectable formulations. We judged laboratory data for a given patient to be complete if all current procedural terminology (CPT) codes for the patient's laboratory tests had corresponding values in the laboratory data file.
Approximately 30% of the CDM population had at least one value in the laboratory database. Given the dramatic increase in testosterone prescribing during the last decade, understanding the extent to which screening and treatment practices are concordant with current clinical practice guidelines is critically important. The developer, David Dzeveckij, indicated that the app’s privacy practices may include handling of data as described below. Some men feel great with low-normal testosterone. Track your testosterone replacement therapy with confidence. You should also see a gynecologist before you start taking any birth control to see if there are any risks of side effects or complications from the changes that contraceptives cause in your hormones.
The Endocrine Society recommends testosterone therapy only in men with low serum testosterone levels, consistent symptoms of hypogonadism, and no signs of prostate cancer. If the clinical signs and symptoms suggest hypogonadism but the serum testosterone level is near normal, then assay of serum testosterone should be repeated in conjunction with SHBG because serum testosterone might be normal in the presence of hypogonadism if the SHBG level is raised, which commonly occurs in elderly male patients. It would be helpful if health care professionals could identify men with low serum testosterone levels who are likely experiencing symptoms purely from androgen deficiency and would therefore benefit from treatment. • Men diagnosed with low testosterone (hypogonadism) seeking improved symptom management• Patients currently on Testosterone Replacement Therapy looking for optimized results• Men exploring or beginning their TRT journey who want to start tracking right away• Individuals looking to optimize their hormone protocols and maximize treatment benefits• Anyone wanting to track their testosterone levels, injection schedule, and related symptomsTRT Tracker helps thousands of men optimize their hormone health and get the most from their treatment. We found that substantial numbers of men receiving testosterone therapy had inadequate screening and monitoring recommendations of the Endocrine Society, and many began treatment despite having testosterone levels in the range considered normal by the Endocrine Society.
However, patients receiving injections of testosterone enanthate or cypionate every 2 weeks will require an earlier measurement of serum testosterone at 1 to 2 weeks after commencement of therapy.3 In cases of primary and permanent secondary hypogonadism diagnosed in the prepubertal male, life long testosterone treatment is needed. If the total testosterone level is normal in the aging male presenting signs of hypogonadism, the clinician can measure free testosterone or measure SHBG and calculate bioavailable testosterone.9 To differentiate primary from secondary hypogonadism, early morning luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels must be obtained.
Men treated by endocrinologists and urologists were more likely to have been treated according to guideline recommendations than men treated by other specialties, including primary care. Among men who were tested, 19.5% did not meet Endocrine Society guidelines for low testosterone. TRT Tracker is the specialized solution designed specifically for testosterone optimization and management. Log doses, injections, labs and symptoms. Log doses, monitor symptoms, and share reports with your doctor. Sign up and start logging your labs and symptoms today.
Our findings show that among men who initiated testosterone therapy from 2001 to 2010, many did not receive pretreatment testosterone or PSA screening concordant with the Endocrine Society's guidelines. As shown in Table 1, older patients, particularly those aged ≥70 years, had lower odds of receiving a serum testosterone test than their younger peers. We present the percentage of testosterone users who received a serum test for testosterone or PSA, or who initiated therapy without evidence of low testosterone or with an elevated PSA value, overall and according to each of the study variables. We included all doses and formulations of testosterone therapy in our analyses. Moreover, the examination of demographic (e.g., age group and region) and clinical (e.g., diagnoses of hypogonadism, osteoporosis, fatigue, and sexual dysfunction) characteristics showed that each of the laboratory database subcohorts was representative of the overall study cohort. For the present study, 25% of the entire study cohort had complete testosterone laboratory values, and 17% had complete PSA laboratory data. In addition, almost one out of five treated men had baseline serum testosterone values above the threshold defined as normal by the Endocrine Society.